CAJ | 학술논문

目的：探讨顺铂(ddP)、异环磷酰胺(ifo)与阿霉素（adM）联合治疗（dia 方案）骨肉瘤的临床疗效。方法对47例骨肉瘤患者应用 dia 方案化疗，并进行随访，平均随访时间为56个月，统计患者5年生存率及转移情况。近期疗效和药物不良反应评价按抗癌药物常见毒副反应分级标准 WHo。结果47例患者中，随访期内5年生存率为66%，12例患者肺转移，1例局部复发，11例死亡；不良反应主要为骨髓抑制和消化道反应。结论 dia 方案化疗方案，可使患者获得较高的长期生存率，耐受性良好，疗效肯定，可作为骨肉瘤的补充化疗方案。
목적：탐토순박(ddP)、이배린선알(ifo)여아매소（adM）연합치료（dia 방안）골육류적림상료효。방법대47례골육류환자응용 dia 방안화료，병진행수방，평균수방시간위56개월，통계환자5년생존솔급전이정황。근기료효화약물불량반응평개안항암약물상견독부반응분급표준 WHo。결과47례환자중，수방기내5년생존솔위66%，12례환자폐전이，1례국부복발，11례사망；불량반응주요위골수억제화소화도반응。결론 dia 방안화료방안，가사환자획득교고적장기생존솔，내수성량호，료효긍정，가작위골육류적보충화료방안。
Objective discussion cisplatin (ddP), ifosfamide (ifo) and adriamycin (adM) combination therapy (dia) clinical efficacy of osteosarcoma. Method in 47 cases of osteosarcoma were treated with dia regimen, and were followed up, the mean follow-up time was 56 months, and statistics were 5 year survival rate and metastasis. The recent efficacy and adverse drug reaction were assessed according to anticancer drugs common toxicity grading standards WHo. Result in 47 patients during the follow-up period, 5 year survival rate was 66%, 12 patients with lung metastasis, 1 cases of local recurrence, 11 cases of death; the main toxicity was myelosuppression and gastrointestinal tract reaction. Conclusion . dia chemotherapy, long-term survival can make patients obtain higher rate, good tolerability, efficacy, can be used as a supplemental chemotherapy of osteosarcoma.